CPGR, SimuGen Enter Into Biomarker Assay Pact | GenomeWeb

NEW YORK (GenomeWeb News) – South Africa's Centre for Proteomic and Genomic Research today said that it has entered into an agreement with SimuGen to develop biomarker assays for the prediction of toxicity of existing and new drug compounds.

SimuGen is a Malaysia-based pharmacogenomics firm working on novel dose-toxicity models for drug development customers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.